Samantha K Gargasz

Ms. Samantha K Gargasz

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Naorem Loya MangangNaorem Loya Mangang
Naorem Loya Mangang
SGSamantha K Gargasz
Samantha K Gargasz
SMSai Ghanesh Murugan
Sai Ghanesh Murugan
MKMUNISH of KUMAR
MUNISH of KUMAR
GSGirish C Shukla
Girish C Shukla
SVSivakumar Vijayaraghavalu
Sivakumar Vijayaraghavalu
Cancer immunotherapy has transformed oncology, but lasting responses are still limited due to resistance mechanisms within the tumor microenvironment. MicroRNAs (miRNAs) have emerged as critical regulators of immune checkpoint pathways, antigen presentation, T-cell activity, and macrophage polarization. By modulating both tumor-intrinsic and immune cell–intrinsic processes, miRNAs influence the efficacy of immune checkpoint inhibitors, therapeutic vaccines, and adoptive cell therapies. Additionally, circulating and exosomal miRNAs are being investigated as minimally invasive biomarkers to predict patient response and resistance to immunotherapy. Clinical trials of miRNA-based treatments, including mimics and inhibitors, have highlighted both the promise and challenges of translating these molecules into clinical use. Advances in delivery systems, RNA chemistry, and combinatorial strategies are paving the way for their integration into precision immuno-oncology. This review offers a comprehensive overview of the mechanistic, biomarker, and therapeutic roles of miRNAs in cancer immunotherapy, highlighting ongoing clinical progress and prospects.